<scp>iGlarLixi</scp> versus basal plus <scp>Rapid‐Acting</scp> insulin in adults with type 2 diabetes advancing from basal insulin therapy: The <scp>SoliSimplify Real‐World</scp> study-Reference-Cited by-同舟云学术

iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

Published:2022-09-19 Issue:1 Volume:25 Page:68-77
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

McCrimmon Rory J.¹^ORCID,Cheng Alice Y.Y.²,Galstyan Gagik³,Djaballah Khier⁴,Li Xuan⁵,Coudert Mathieu⁴,Frias Juan P.⁶

Affiliation:

1. Division of Systems Medicine, School of Medicine University of Dundee Dundee UK

2. Department of Medicine University of Toronto Toronto Ontario Canada

3. Diabetic Foot Department Endocrinology Research Center Moscow Russia

4. Sanofi Paris France

5. Sanofi Bridgewater New Jersey USA

6. Velocity Clinical Research Los Angeles California USA

Funder

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14844

Reference36 articles.

1. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022

3. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis

4. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes

5. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification;Diabetes Therapy;2024-06-27

2. Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel;Diabetes Therapy;2024-03-12

3. Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials;Diabetes Research and Clinical Practice;2024-03

4. Innovative Solution for Kids with Diabetes: Augmented Reality Mobile Application for Insulin Intake;CSR, Sustainability, Ethics & Governance;2024

5. The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review;Advances in Therapy;2023-06-16